Neoadjuvant camrelizumab combined with radiotherapy as a chemotherapy-sparing approach for resectable locally advanced esophageal squamous cell carcinoma: a phase II clinical trial (ESOCORT-NIRT)
Neoadjuvant camrelizumab plus radiotherapy showed low toxicity, pathologic tumor regression, and favorable postoperative outcomes in resectable esophageal squamous cell carcinoma. This chemotherapy-sparing approach may be an alternative for patients who are unsuitable for or intolerant of standard chemotherapy-based neoadjuvant regimens.
Authors
- Yizhou Huang (ORCID: https://orcid.org/0000-0002-5523-4360)
- Maohui Chen (ORCID: https://orcid.org/0000-0002-2064-8715)
- Zhenyuan Yang
- Hongmu Li (ORCID: https://orcid.org/0000-0002-7194-4274)
- T. Zeng
- Chuanquan Lin
- Bin Zheng
- Chun Chen
- Wei Li
- Cheng Chen
- Benhua Xu
- Shuliang Zhang
Institutions
- Fujian Medical University (CN)
- Education Department of Fujian Province (CN)
- Union Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1186/s12916-026-04781-4
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00